#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this information to counsel patients about cardiovascular risks associated with cannabis use, particularly when patients present with chest pain, palpitations, or stroke symptoms without traditional risk factors. Understanding cannabis as a potential contributor to acute cardiac events allows providers to take more complete substance use histories and make informed risk-benefit assessments when patients ask about cannabis safety or are considering use alongside existing cardiovascular disease.
A recent observational study has identified associations between cannabis use and increased risk of acute cardiovascular events including myocardial infarction and stroke, with some users demonstrating substantially elevated event rates compared to non-users. The findings raise important clinical concerns given the growing normalization and medical use of cannabis, particularly among patients with existing cardiovascular risk factors or established disease who may not disclose use to their physicians. Clinicians should recognize that cannabis use—whether smoked, vaporized, or ingested—may trigger acute coronary syndromes or cerebrovascular events through multiple proposed mechanisms including sympathomimetic effects, thrombotic changes, and endothelial dysfunction. The study underscores a significant gap in clinical knowledge, as cannabis-related cardiovascular complications are often underrecognized and underreported in both patient histories and adverse event documentation. Physicians caring for patients with cardiovascular disease or risk factors should proactively screen for cannabis use during history-taking and counsel patients about potential cardiac risks, while documenting any use in the medical record to inform clinical decision-making and risk stratification. Clinicians should counsel patients about cardiovascular risks associated with cannabis use and maintain a high index of suspicion for cannabis as a potential contributor when evaluating acute cardiac or cerebrovascular events in users.
“What this data tells us is that we can no longer treat cannabis as a benign substance in cardiovascular risk assessment, particularly for patients over 50 or those with existing hypertension or arrhythmias. The mechanism appears real—acute cannabinoid effects on heart rate and blood pressure can be dangerous in vulnerable populations—but we still need better data on dose, frequency, and product type to counsel patients responsibly rather than categorically.”
? Recent observational data linking cannabis use to increased risk of myocardial infarction and stroke warrants careful clinical attention, though the strength of causation remains uncertain given the cross-sectional or case-control nature of most available evidence. Cannabis smoke contains known cardiotoxic compounds and can acutely elevate heart rate and blood pressure, but confounding factors including concurrent tobacco use, underlying cardiovascular risk profiles, and the wide variability in cannabis products and consumption methods complicate interpretation of population-level associations. Clinicians should recognize that cannabis users represent a diverse group with heterogeneous risk factors, and that individual susceptibility to cardiovascular effects likely depends on dose, frequency, route of administration, and baseline health status. When taking patient histories, healthcare providers should inquire specifically about cannabis use as part of standard cardiovascular risk assessment, particularly in younger populations where cannabis use may be normalized but cardiac risk can still be significant. Counseling patients
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
